21.73
0.34 (1.59%)
| 前收盘价格 | 21.39 |
| 收盘价格 | 21.29 |
| 成交量 | 1,584,429 |
| 平均成交量 (3个月) | 2,107,160 |
| 市值 | 3,666,116,608 |
| 市盈率 (P/E TTM) | 16.34 |
| 预期市盈率 (P/E Forward) | 20.75 |
| 价格/销量 (P/S) | 3.51 |
| 股市价格/股市净资产 (P/B) | 4.39 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2025 |
| 营业毛利率 | 22.97% |
| 营业利益率 (TTM) | 7.90% |
| 稀释每股收益 (EPS TTM) | 1.37 |
| 季度收入增长率 (YOY) | 18.70% |
| 季度盈利增长率 (YOY) | 14.70% |
| 总债务/股东权益 (D/E MRQ) | 7.32% |
| 流动比率 (MRQ) | 2.88 |
| 营业现金流 (OCF TTM) | 148.96 M |
| 杠杆自由现金流 (LFCF TTM) | 19.27 M |
| 资产报酬率 (ROA TTM) | 5.56% |
| 股东权益报酬率 (ROE TTM) | 37.24% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | ACADIA Pharmaceuticals Inc. | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | -2.0 |
| 平均 | -0.88 |
|
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.57% |
| 机构持股比例 | 104.46% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 40.00 (RBC Capital, 84.08%) | 购买 |
| 中 | 33.00 (51.86%) | |
| 低 | 17.00 (Goldman Sachs, -21.77%) | 卖出 |
| 平均值 | 32.00 (47.26%) | |
| 总计 | 7 购买, 1 保留, 1 卖出 | |
| 平均价格@调整类型 | 23.39 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Citigroup | 21 Oct 2025 | 33.00 (51.86%) | 购买 | 21.27 |
| JP Morgan | 29 Sep 2025 | 33.00 (51.86%) | 购买 | 21.32 |
| Needham | 24 Sep 2025 | 28.00 (28.85%) | 购买 | 21.26 |
| TD Cowen | 11 Sep 2025 | 39.00 (79.48%) | 购买 | 24.20 |
| UBS | 09 Sep 2025 | 39.00 (79.48%) | 购买 | 24.84 |
| 08 Aug 2025 | 36.00 (65.67%) | 购买 | 24.60 | |
| Goldman Sachs | 07 Aug 2025 | 17.00 (-21.77%) | 卖出 | 24.40 |
| JMP Securities | 07 Aug 2025 | 35.00 (61.07%) | 购买 | 24.40 |
| Mizuho | 07 Aug 2025 | 24.00 (10.45%) | 保留 | 24.40 |
| RBC Capital | 07 Aug 2025 | 40.00 (84.08%) | 购买 | 24.40 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合